Phase 2 Parkinson's Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older.
• People who are able to give signed consent to participate.
• People who are willing and able to follow all study procedures throughout the trial.
• People who are able to swallow and take tablets or capsules by mouth.
• Women who could become pregnant and are sexually active must be willing to use two forms of highly effective contraception (such as condoms, diaphragm, hormonal contraception, or an intrauterine device) for the full duration of the trial and for 28 days after finishing the study medication.
• Men who could father a child and are sexually active must be willing to use a male condom, and their partner must also use an effective contraceptive method (such as hormonal contraception, an intrauterine device, or a barrier method) for the full duration of the trial and for 28 days after finishing the study medication.
• People who have been diagnosed with Parkinson's disease according to established UK diagnostic criteria, which includes slowness of movement plus at least one of: muscle stiffness, a specific type of resting tremor, or balance problems — along with at least three additional supporting features such as symptoms starting on one side of the body, a strong response to a medication called levodopa, or symptoms that have progressed over time.
• People who have been diagnosed with functional constipation under recognised international criteria, which specifically requires having three or fewer bowel movements per week, plus at least one other constipation symptom (such as straining, hard stools, a feeling of incomplete emptying, a sense of blockage, or needing to use manual methods to pass a stool), with these symptoms present for at least three months and starting at least six months before diagnosis.

Who may not be able to join:

• People diagnosed with an atypical form of parkinsonism (a related but different condition).
• People whose parkinsonism is caused by medication.
• People whose parkinsonism is caused by problems with blood flow to the brain (vascular parkinsonism).
• People with a known allergy to pyridostigmine bromide or any other ingredient in the study drug.
• People who have used pyridostigmine for any reason within the 90 days before enrolling.
• People who have had any bowel surgery at any point in their life.
• People who have a history of bladder or bowel obstruction.
• People with severe asthma or severe chronic lung disease (COPD).
• People whose medical history includes features that, in the opinion of the trial doctor, rule out a Parkinson's disease diagnosis under UK Brain Bank Criteria — such as a history of repeated strokes or head injuries, a history of encephalitis, certain eye movement problems, use of antipsychotic medication at the time symptoms began, more than one affected family member, periods of full recovery, specific neurological signs, early severe memory problems, a tumour in the brain, no response to high doses of levodopa, or exposure to a specific toxic substance known as MPTP (confirm with trial site).
• People with significant abnormal results on blood tests (such as full blood count, metabolic panel, or thyroid hormone levels) taken at the screening visit or within the previous three months.
• People with significant abnormal results on a heart tracing (ECG) taken at the screening visit or within the previous three months.
• Women of childbearing age who have a positive pregnancy test.
• People who have taken antibiotics within two weeks before enrolling in the trial.

Important: Always verify eligibility with the trial site directly before applying.